CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Binimetinib +1 moredrug
Likely dose
Binimetinib 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03843775
NCT03843775Phase 2Completed
CompareCT.gov

A Phase I/II Study of Binimetinib With Encorafenib in Patients With Non-V600 Activating BRAF Mutant Advanced Malignancies

Memorial Sloan Kettering Cancer Center·interventional·Posted Feb 18, 2019·Updated Oct 21, 2024

In Brief

A Phase 2 clinical trial evaluating Binimetinib and Encorafenib for Advanced BRAF Mutant Cancers. Completed, enrolled 17 participants across 4 sites.

Detailed Summary

The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced BRAF Mutant Cancers
CountriesUnited States
CollaboratorsArray BioPharma

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 18, 2019
Enrollment StartFeb 14, 2019
Primary CompletionSep 2, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.4 years ago

Interventions

Binimetinibdrug

Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID

Encorafenibdrug

encorafenib 450 mg oral QD